share_log

Vigil Neuroscience Presented Data Highlighting Its Oral Small Molecule Program, Including Its Lead Clinical Candidate VG-3927, In Two Oral Presentations At The AD/PD 2025 International Conference On Alzheimer's And Parkinson's Diseases

Benzinga ·  Apr 2 11:02
  • Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927.
  • First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
1
Comment Comment · Views 308

Recommended

Write a comment